Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Risk OfficerHold
Generated at:2026-04-18 05:49:06
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-04-17
  • First, the overhead supply at $238-$242 is a material, immediate risk, as highlighted by the Conservative Analyst. This technical headwind successfully counters the Aggressive view that negative sentiment is overdone, making a full BUY now akin to 'catching a falling knife' without a confirmed reversal signal.
  • Furthermore, the Aggressive Analyst correctly defends the strong fundamental thesis (validated Q1 earnings, dividend safety). Therefore, a blanket SELL recommendation would be an overreaction to technical weakness, as selling here risks missing a rebound fueled by these acknowledged strong fundamentals.
  • More importantly, the Neutral Analyst provides the crucial bridge: a HOLD is an active decision to require proof before committing new capital. This enforces the disciplined part of the original plan ('Entry on close above $238') that was being overlooked, making HOLD a strong, specific choice to wait for technical confirmation of the fundamental opportunity.
  • In addition, past mistakes remind us that acting on oversold conditions (RSI ~27) alone, without a confirming price action signal, often leads to premature entries. The committee's decision applies this lesson by requiring the specific signal of a daily close above $238 to validate the entry.
  • Strong fundamentals (validated Q1 earnings, upgrades, robust dividend) are disconnected from an oversold technical condition (RSI ~27).
  • This creates a classic contrarian entry point for a move to the $252 target price.
  • The defensive nature of Johnson & Johnson inherently limits downside risk.
  • Both the Aggressive and Conservative analysts have valid points.
  • Jumping in now is speculative, while selling ignores fundamental strength.
  • The optimal path is to acknowledge the opportunity but demand technical confirmation.
  • A 'hold' on new action is warranted until price proves it can overcome immediate resistance.
  • Strategy should be to 'wait for price to break through key resistance for confirmation.'
  • All positive news is already priced into the stock.
  • The technical picture is decisively bearish, with price below key moving averages and facing strong overhead resistance ($238-$242).
  • The high P/E ratio of 26.85 offers no margin of safety.
  • The prudent action is to reduce risk and wait for a confirmed technical recovery.
  • Entering a full position now is 'catching a falling knife' without a confirmed reversal signal.

Decision

Decision summary

The committee finds the Neutral Analyst’s framework to be the most risk-conscious and aligned with the principles of capital preservation while ackno

wledging opportunity. A decisive BUY or SELL is not justified at this precise moment. The core rationale is to require technical confirmation before committing new capital, specifically a daily close above $238.00 to validate the bullish fundamental thesis. The strategy is an active hold for a specific signal, enforcing the disciplined part of the original trader plan. Key risk management includes a unified stop-loss at $229.90 and a refined profit-taking target of $238-$242 initially, with the original $252 target to be reevaluated. The risk-reward is favorable only upon a confirmed breakout.

Trader plan

Execution plan
  1. Immediate Action (HOLD): Do not initiate a new buy order at $234.18. Maintain any existing position.
  1. Trigger for Action: Place an alert for a daily closing price above $238.00. This confirms a break of the nearest technical resistance and validates the bullish fundamental thesis.
  2. Action upon Trigger: If triggered, initiate a scaled entry:
    • First 50% of the intended position size upon the close above $238.
    • Second 50% on a subsequent pullback to the $238 breakout level (now support) or on a further close above $240.
  3. Risk Management:
    • Unified Stop-Loss: $229.90 for any position (existing or new), as per the original plan. This level is just below the major $230 support and limits downside to ~1.8% from current price.
    • Profit Taking: Adopt the Neutral Analyst’s more conservative initial target range of $238 - $242 for partial profit-taking, then reevaluate for the original $252 target.
  4. Abort Condition: If the price declines and hits the stop-loss at $229.90 without first triggering our buy signal ($238+ close), the trade is invalidated. No position should be taken.
AI Risk Assessment Discussion
Round-by-round arguments
Round 1

Round 1 · Aggressive

  • 演讲者强烈建议买入JNJ股票,批评保守分析师过度依赖技术面看跌信号,认为当前超卖是机会
  • 同时批评中性分析师因增长担忧而建议持有,忽略了积极基本面
  • 强调积极财报、调高目标价及防御性,目标价252美元

Detail Preview

Alright, let's cut through the noise. I’ve reviewed the trader’s BUY call on JNJ, and I’m here to tell you why the conservative and neutral analysts are about to miss a major opportunity by hiding behind technical charts and modest growth narratives. First, to the conservative analyst fixated on the technical "bearish stack" and overhead supply: you’re looking backward, not forward. Yes, the stock is below its moving…

Round 1 · Neutral

  • 中立分析师指出,激进派忽视技术面阻力,保守派忽略基本面利好
  • 平衡策略建议分批建仓,在现价附近开始,于支撑位加仓,止损设在230美元以下,目标盈利区间为238至242美元

Detail Preview

The aggressive analyst sees a screaming buy in this oversold condition, and the conservative analyst sees a technical breakdown to avoid. As a neutral analyst, my role is to show you why both views, taken to their extremes, are flawed and why the most reliable path lies directly between them. Let's start with the aggressive view. They are correct that the fundamental news is exceptionally strong: a stellar Q1, a rais…

Round 1 · Conservative

  • 保守分析师反驳买入建议,认为多数利好已消化且技术面呈下跌趋势,指出负债率高、估值风险及关键技术位阻力,主张避险并建议现有持仓者逢反弹减仓

Detail Preview

Let me start by addressing the aggressive analyst's position. You're focusing heavily on the positive news flow—the Barclays upgrade, the Q1 results, the dividend increase—and using that to justify a buy. But from a conservative standpoint, that's exactly where the danger lies. You're chasing headlines while the technical structure is crumbling. The market has already rewarded JNJ with a 55% gain over the past year;…

Round 2

Round 2 · Aggressive

  • 演讲者反驳保守分析师的观点,认为其技术分析滞后且忽视了最新基本面数据(如机构调升目标价),并批评中立分析师的目标过于保守,错失了增长潜力
  • 演讲者强调公司基本面强劲、技术面超卖,主张采取更积极的投资策略

Detail Preview

Let me address both of you directly. Conservative analyst, your entire argument hinges on technical patterns and fear of what's already happened. You're looking backward while we should be looking forward. You claim the "majority of positives are already priced in," but that's demonstrably false based on the fresh data. Barclays just raised their target to $255 less than 24 hours ago—that's new information the market…

Round 2 · Neutral

  • 该发言指出两位分析师观点各有依据,但均存在风险
  • 建议采取折中策略:认可基本面机会,但需谨慎分批建仓,严格设置止损,并等待价格突破关键阻力位确认趋势

Detail Preview

Let's step back and look at this objectively. Both of you are making valid points, but you're each anchored to one side of the story, and that's where the risk lies. Aggressive analyst, your enthusiasm for the fundamentals is justified. The Q1 numbers, the dividend hike, and the Barclays upgrade to $255 are powerful, fresh catalysts. You're right that waiting for perfect technical alignment often means missing the in…

Round 2 · Conservative

  • 演讲者批评激进与中性分析师的观点,认为两者都忽视了实际风险
  • 他指出,利好消息已被市场消化,技术指标显示下跌趋势明确,当前买入如同徒手接刀
  • 他强调应以资本保全为先,建议等待股价重回关键均线并企稳后再行动

Detail Preview

I understand the aggressive analyst's enthusiasm for the fundamentals, and the neutral analyst's attempt at balance, but both approaches expose the firm to unnecessary and quantifiable risk. My conservative stance is not about ignoring positive news; it's about recognizing that this news is already widely known and is failing to counteract a clear and present technical deterioration. Let me address their points direc…

Assessment complete